All In Biotech

Drug Trial Radar · NCT04865770

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

Renal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

106

Actual

Start

Apr 28, 2021

Primary completion

Nov 21, 2024

Study completion Nov 21, 2024

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Apr 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys. Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance. Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine into the skin once a week. The study will last for about 1 year. Participants will have 11 visits to the clinic, and 2 phone visits. Some of the visits could be in different locations. Study staff will take blood samples at most of these visits. At 9 visits, participants will be asked to bring a sample of their first morning urine. At 4 of the visits participants will have to bring urine that they have collected over the last 24 hours. The study includes magnetic resonance imaging (MRI) scans of participants' kidneys which is a test that shows a detailed picture of organs and other parts inside the body. The scan will last for 30 minutes, and is free of radiation.

Conditions

  • Diabetes Mellitus, Type 2
  • Chronic Kidney Disease

Interventions

  • SemaglutideDrug

    Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.

  • Placebo (Semaglutide)Drug

    Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*)Time frame: Baseline (week 0), End of treatment (week 52)
  2. Change in Kidney Oxygenation (Medulla), BOLD MRI (R2*)Time frame: Baseline (week 0), End of treatment (week 52)
  3. Change in Global Kidney Perfusion (MRI)Time frame: Baseline (week 0), End of treatment (week 52)
  4. Change in Kidney Inflammation (Cortex), Longitudinal Relaxation Time (T1) Mapping (MRI)Time frame: Baseline (week 0), End of treatment (week 52)
  5. Change in Kidney Inflammation (Medulla), T1 Mapping (MRI)Time frame: Baseline (week 0), End of treatment (week 52)

Locations

49 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Arizona-CaTs

    Tucson, Arizona

  • Academic Medical Research Institute

    Los Angeles, California

  • Roderick A. Comunale II MD Inc.

    National City, California

  • N America Res Inst - San Dimas

    San Dimas, California

  • UC Anschutz Medical Campus

    Aurora, Colorado

  • Advent Health-Res Inst

    Orlando, Florida

  • Atlanta Diabetes Associates

    Atlanta, Georgia

  • Emory University Hsptl - Atlanta

    Atlanta, Georgia

  • Endeavor Health Glenbook Hosp

    Evanston, Illinois

  • North Suburban Nephrology LLC

    Gurnee, Illinois

  • University of Minnesota Health Clinical

    Minneapolis, Minnesota

  • Clinical Research Consultants, LLC

    Kansas City, Missouri

  • Cleveland Clinic_Cleveland

    Cleveland, Ohio

  • Prolato Clinical Research Cntr

    Houston, Texas

  • Sun Research Institute

    San Antonio, Texas

  • NE Clin Res of San Antonio

    San Antonio, Texas

  • University of Texas San Antonio

    San Antonio, Texas

  • Univ of Washington Med Ctr

    Seattle, Washington

  • Providence Medical Research Center

    Spokane, Washington

  • Medical College Of Wisconsin

    Milwaukee, Wisconsin

  • LMC ClinRsrh Inc.Brampton

    Brampton, Ontario, Canada

  • UHN-Toronto General Hospital

    Toronto, Ontario, Canada

  • Nefrologisk Klinik P 2132

    Copenhagen, Denmark

  • Rigshospitalet - Nefrologisk Klinik P 2132

    Copenhagen, Denmark

  • Steno Diabetes Center Copenhagen

    Herlev, Denmark

  • Centre Hospitalier Universitaire Amiens Picardie-Site Sud

    Amiens, France

  • Centre Hospitalier Universitaire de Rouen - Hopital de Bois Guillaume

    Bois-Guillaume, France

  • Centre Hospitalier Universitaire Grenoble Alpes-Site Nord Michallon-2

    Grenoble - Cédex 09, France

  • Les Hopitaux de Chartres-Hopital Louis Pasteur

    Le Coudray, France

  • Chu de Reims-Hopital Maison Blanche

    Reims, France

  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil

    Toulouse, France

  • Azienda Ospedaliera Papa Giovanni XXIII

    Bergamo, Italy

  • Azienda Ospedaliera di Padova Clin.Med.3

    Padova, Italy

  • Presidio Ospedaliero Cisanello

    Pisa, Italy

  • Azienda Ospedaliero - Universitaria Sant'Andrea

    Roma, Italy

  • Istituto Scientifico San Raffaele

    Milan, MI, Italy

  • In-Vivo Sp. z o.o.

    Bydgoszcz, Poland

  • Centrum Medyczne "Diabetika"

    Radom, Poland

  • Uniwersytecki Szpital Kliniczny Nr 2 PUM W Szczecinie

    Szczecin, Poland

  • Miedzyleski Szpital Specjalistyczny, Oddzial Nefrologiczny

    Warsaw, Poland

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.